Clinical Manual for Management of the HIV-Infected Adult, 2006 Edition

Section 6: Disease-Specific Treatment

Candidiasis, Vulvovaginal

URL: http://aidsetc.org/aidsetc?page=cm-505_candidiasis_vulvo

Background

Vulvovaginal candidiasis is a yeast infection caused by several types of Candida , typically Candida albicans . This disease is common in all women, but may occur more frequently and more severely in immunocompromised women.

Although refractory vaginal Candida infections by themselves should not be considered indicators of HIV infection, they may be the first clinical manifestation of HIV infection, and can occur early in the course of disease (at CD4 counts >500 cells/µL). The frequency of vaginal candidiasis tends to increase as CD4 counts decrease; this may, however, be due in part to increased antibiotic use among women with advanced HIV infection.

Risk factors for candidiasis include diabetes mellitus and the use of oral contraceptives, corticosteroids, or antibiotics.

S: Subjective

The patient may complain of itching, burning, or swelling of the labia and vulva; a thick white or yellowish vaginal discharge; painful intercourse; and pain and burning on urination.

The most important elements in the history include:

O: Objective

A focused physical examination of the external genitalia may reveal inflammation of the vulva with evidence of discharge on the labial folds and vaginal opening. Speculum examination usually reveals a thick, white discharge with plaques adhering to the vaginal walls and cervix. Bimanual examination should not elicit pain or tenderness and otherwise should be normal.

A: Assessment

Rule out other causes of vaginal discharge and pruritus:

P: Plan

Diagnostic Evaluation

A presumptive diagnosis is made on the basis of the clinical presentation and potassium hydroxide (KOH) preparation:

Treatment

Uncomplicated infections

Topical medications

Note that the mineral-oil base in topical vaginal antifungal preparations may erode the latex in condoms, diaphragms, and dental dams. Advise the patient to use alternative methods to prevent HIV transmission or conception, or to discontinue intercourse while using these medications. Nonlatex condoms (plastic and polyethylene only) or "female" condoms (polyurethane) can be used.

Oral medications

Complicated infections

Severe or recurrent candidiasis

Severe or recurrent candidiasis is defined as 4 or more episodes within 1 year. Consider the following treatments:

For severe cases that recur repeatedly, secondary prophylaxis can be considered, eg, clotrimazole vaginal suppository (500 mg once weekly) or oral fluconazole (100-200 mg weekly).

Non- albicans candidiasis
Treatment notes

Patient Education

References

  • Abularach S, Anderson J. Gynecologic Problems . In: Anderson JR, ed. A Guide to the Clinical Management of Women with HIV. Rockville, MD: Health Resources and Services Administration, HIV/AIDS Bureau; 2005. Available online at hab.hrsa.gov/publications/womencare05/. Accessed May 19, 2006.
  • Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006 . MMWR 2006;55(No. RR-11):1-100.
  • U.S. Public Health Service, Infectious Diseases Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons--2002 . MMWR Recomm Rep. 2002 Jun 14;51(RR08);1-46. Available online at aidsinfo.nih.gov/Guidelines/. Accessed May 19, 2006.
  • Cohn SE, Clark RA. Sexually transmitted diseases, HIV, and AIDS in women . In: The Medical Clinics of North America, Vol. 87; 2003:971-995.
  • Hatcher RA, Stewart FH, Trussell J, et al. Contraceptive Technology, 15th ed . New York: Ardent Media; 1999:123-5.
  • Sande MA, Eliopoulos GM, Moellering RC, et al. The Sanford Guide to HIV/AIDS Therapy, 14th ed . Hyde Park, VT: Antimicrobial Therapy, Inc.; 2005.
  • Spence D. Candidiasis (vulvovaginal) . Clin Evid. 2004 Dec;(12):2493-511.